Brought to you by 
Cerulean licenses Calando's delivery platform, candidate
19 Oct 2015
Executive Summary
Arrowhead Research Corp.'s Calando Pharmaceuticals (nanoparticle drug conjugates) has granted Cerulean Pharma (nanopharmaceuticals) exclusive worldwide rights to its Cyclosert drug delivery platform, and its anticancer candidate IT101.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cerulean licenses Calando's delivery platform, candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice